Despite evidence of durable responses, currently approved antibodies against the immune regulators CTLA4 and PD-1/PD-L1 in lung cancer are effective only in subsets of patients, and resistance after an initial response may occur. The gene discussed is PDCD1; the disease is lung carcinoma.